TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive DCCP Funds 57 Percent Of Epidemiology R01a In FY 1981, Less In 1982 But Still Above The Average For All NCI October 2, 1981
TCL Archive NCI To Fund About 4,100 Grants; Increase Planned In Average Costs; Paylines Stable November 20, 1998
TCL Archive In Brief: FDA To Review Preclinical Testing, Phase I Protocols At Open Advisory Group Meeting November 14, 1975
TCL Archive FDA Approves Cyramza for Stomach Cancer; Zykadia in NSCLC; Lipiodol for HCC Imaging; And Cobas HPV Test for Primary Screening April 25, 2014
